---
title: "Enhancing Medication Safety During Pregnancy: Research Insights"
id: "plos-medicine-0-towards-improving-the-safety-of-medication-use-in-pregnancy"
canonical_url: "https://medichelpline.com/clinical-feed/plos-medicine-0-towards-improving-the-safety-of-medication-use-in-pregnancy"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "PLOS Medicine"
source_url: "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291"
published_at: "2026-11-16T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Enhancing Medication Safety During Pregnancy: Research Insights
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-medicine-0-towards-improving-the-safety-of-medication-use-in-pregnancy
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** PLOS Medicine
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291)
- **Published At:** 2026-11-16T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Pregnant individuals are often missing from clinical trials, leading to limited safety data on medications. - Historical cases, like thalidomide, highlight the risks of drug use. - Most medication safety data derives from observational studies due to the exclusion from trials, yet these studies face challenges like confounding factors. - Recent findings indicate low risks for certain medications, yet ambiguity remains around effects on mental development. - A multi-faceted approach, including better data collection and registry utilization, is needed to improve medication safety understanding during pregnancy.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosmedicine%2Farticle%3Fid%3D10.1371%2Fjournal.pmed.1005291) * * About * Browse * Publish * [](https://journals.plos.org/plosmedicine/ "PLOS Medicine") * Search [advanced search](https://journals.plos.org/plosmedicine/search) * 0 [Save](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#savedHeader) * 0 [Citation](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#citedHeader) * 33 [View](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#viewedHeader) * 0 [Share](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291#discussedHeader) Open Access Editorial # Towards improving the safety of medication use in pregnancy * Jennifer Jardine, Roles Conceptualization, Writing – original draft, Writing – review & editing Affiliation Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, United Kingdom ⨯ * Suzanne de Bruijn , Roles Conceptualization, Writing – original draft, Writing – review & editing * E-mail: Sbruijn@plos.org Affiliation Public Library of Science, Cambridge, United Kingdom [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-7429-0448 ](https://orcid.org/0000-0002-7429-0448 "ORCID Registry") ⨯ * on behalf of the PLOS Medicine staff editors ¶Membership of the PLOS Medicine staff editors is provided in the Acknowledgments. ⨯ # Towards improving the safety of medication use in pregnancy * Jennifer Jardine, * Suzanne de Bruijn, * on behalf of the PLOS Medicine staff editors ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: November 16, 2026 * * [Article](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291) * [Authors](https://journals.plos.org/plosmedicine/article/authors?id=10.1371/journal.pmed.1005291) * [Metrics](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005291) * [Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005291) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pmed.1005291) * [Abstract](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#abstract0) * [Acknowledgments](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#ack) * [References](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#references) * [Reader Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005291) Pregnant people are historically excluded from clinical trials, meaning safety information regarding medication use during pregnancy is scarce. Despite efforts to change this, inclusion of pregnant people in trials is complicated. Observational studies may represent the most effective and timely method to close this evidence gap, but guidelines to optimise their value are needed. **Citation:** Jardine J, de Bruijn S, on behalf of the PLOS Medicine staff editors (2026) Towards improving the safety of medication use in pregnancy. PLoS Med 23(11): e1005291. https://doi.org/10.1371/journal.pmed.1005291 **Published:** November 16, 2026 **Copyright:** © 2026 Jardine, de Bruijn. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. **Funding:** The author(s) received no specific funding for this work. **Competing interests:** I have read the journal’s policy and the authors of this manuscript have the following competing interests: SDB is a paid employee of Public Library of Science. JJ is an Academic Editor for PLOS Medicine. Pregnancy can be an uncertain time. During a period when concerns about one’s health and wellbeing are often heightened, it is unclear whether (and which) medications are safe to take for both the pregnant person and the developing baby. The thalidomide scandal of the 1950s and 1960s, when a drug prescribed for morning sickness caused fetal abnormalities and miscarriage, is a searing reminder of the potential risk of medication in pregnancy [[1](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref001)]. More recently, associations between antiepileptics and neurocognitive delay [[2](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref002)], as well as publicised concerns about associations between acetaminophen/paracetamol and neurodevelopmental differences, illustrate that the issue remains prevalent. At the same time, most pregnant people take medication, with antiemetics, antibiotics and analgesics most often used [[3](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref003)]. A recent systematic review put the prevalence of prescribed medication use at 56%, although estimates vary widely [[3](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref003)], and the true figure is likely to be higher once over-the-counter medication and supplements are included. It is also expected to rise further given global trends showing that more people are having children later in life, when people are more likely to have comorbidities that require treatment. How, then, do we establish which medications are safe to take during pregnancy? Because pregnant women have historically been excluded from trials, most safety data come from observational studies, several of which have recently published in _PLOS Medicine_. For example, Hasidim and colleagues found no association between first-trimester nonsteroidal anti-inflammatory drugs (such as ibuprofen) exposure and major congenital malformations [[4](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref004)]. For antibiotics, recent studies found no association between first-trimester macrolide use and major malformations [[5](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref005)], or between overall exposure and childhood autoimmune disease [[6](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref006)]. A meta-analysis by Shakhshir and colleagues found an association between beta-2-adrenergic agonists—the most common inhaled asthma medication—and autism spectrum disorder, although the authors state that the evidence is inconclusive as confounding by indication cannot be ruled out [[7](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref007)]. Although such observational studies are important, there are several challenges in using them to make firm conclusions. First, there are high risks of confounding by indication: for the mother, treatment of preexisting and pregnancy-related conditions may be safer than providing no treatment. Maternal wellbeing shapes fetal health, and this must be set against the risk of medication exposure; mothers with severe illness are more likely to miscarry, and their babies are more likely to be preterm or small [[8](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref008)]. Where the benefit to the mother is clear, as with medications for cystic fibrosis and epilepsy, the case for waiting on long-term fetal data is weaker than for maternal disorders where pausing treatment has fewer adverse consequences, such as dermatoses or mild allergies. Furthermore, some outcomes, such as neurodevelopmental differences, take years to emerge. And in emergencies with high maternal morbidity and mortality, as in the COVID-19 pandemic, decisions may need to be made before any evidence exists. Trials have so far offered limited help. Pregnant people were represented in only 1.1% of clinical trial applications submitted to the UK regulator between 2019 and 2023 [[9](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref009)], so initial evidence of safety and efficacy cannot be translated to this population. Recently, the US Food and Drug Administration and the European Medicine Agency have changed their guidelines to promote inclusion of pregnant people in certain scenarios [[10](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref010),[11](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref011)]. However, removing exclusions will not by itself close the evidence gap. Trial design can be complicated by the inclusion of pregnancy: few participants may get pregnant, and they may be pregnant for only part of a trial. Physiological changes during pregnancy lead to an increased likelihood of developing new conditions or complications; therefore including pregnant people in trials may require a larger number of patients to be enrolled for the study to be adequately powered. Furthermore, showing efficacy in pregnancy will often need adequate power for subgroup analyses in the pregnant population alone. Observational studies will therefore remain central to efforts to understand drug safety during pregnancy. Administrative datasets offer fertile ground for pharmacovigilance and, increasingly, for approaches such as target trial emulation. But, as Yuen and Man note in a recent Perspective, the ‘causal elephant in the room’ is that temporal relationships are rarely clean, and both exposures and pregnancy itself change over time [[12](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref012)]. Careful modelling of time, co-exposures (including other treatments and the underlying illness), and the course of pregnancy are essential. Moreover, due to the requirement for large registries and the need for linkage between records of mothers and their children, such studies are at present mainly only possible in higher-income settings, and their findings may not translate to low-income settings, where different factors may affect associations between medication and their effect on the mother and baby. So how can we generate data on the safety of medications faster and more efficiently? First, we need to create reporting systems that can capture all data generated on any drug used during pregnancy in a single place. This includes data from those who become pregnant during trials or who take medication before knowing they are pregnant, and from case reports. It also includes data from drug safety reporting and information services, such as the European Network of Teratology Information Services, which advises clinicians and patients on individual exposures and can follow up exposed pregnancies. Registries, which remain a key data source, should record precise gestational age at exposure and dose to allow dose–response analyses. Harmonising collection across registries would make datasets easier to combine. Better linkage of maternal and child records is also needed, with long-term follow-up for outcomes that emerge later, such as neurodevelopment. Finally, these registry studies should be performed more systematically. One option could be for legislation changes that require pharmaceutical companies to ensure registry studies are completed for every drug that they bring to market, rather than waiting for researchers and charity funders to fill the gap. Epidemiological data should also be complemented by pharmacological evidence on whether and when during pregnancy a medicine crosses the placenta. Ex vivo placental perfusion, cell models and physiologically based pharmacokinetic modelling can estimate fetal exposure [[13](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref013)]. Measuring drug exposure biomarkers in cord blood, neonatal blood spots or hair can further quantify fetal exposure. This can help prioritise safety questions and judge whether observed associations are biologically plausible. Finally, better data alone is not enough: methods for these studies also need to be discussed and agreed. The population is complex. Perinatal stages are not always easy to define, and effects on offspring can arise at different points in pregnancy, with some, such as early pregnancy loss, being hard to record [[14](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005291#pmed.1005291.ref014)]. It is therefore crucial to agree on a framework for analysing this data, which may differ by class of medication. Ultimately, collaborative and systematic efforts are needed to promptly perform these analyses for all appropriate medications. At _PLOS Medicine_ , we welcome studies that contribute robust evidence on the effects and safety of medications during pregnancy, as well as guidelines aimed at improving the methodology, consistency and reporting of such studies to the highest standard. Although pregnancy will always be an uncertain time, strengthening the evidence on medication safety during pregnancy will simultaneously help to improve maternal and fetal health, reduce fears and anxiety around medication use, and close the health equity gap for pregnant people. ## Acknowledgments Thank you to the PLOS Medicine Staff Editors for feedback on this Editorial (Andreia Cunha, Alison Farrell, Daniel Routledge, Helen Lumbard, Katarzyna Starowicz and Manpreet Kaur). ## References 1. 1. Vargesson N. Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–56. pmid:26043938 * [ View Article ](https://doi.org/10.1002/bdrc.21096 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/26043938 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Thalidomide-induced+teratogenesis%3A+History+and+mechanisms+Vargesson+2015 "Go to article in Google Scholar") 2. 2. Madley-Dowd P, Ahlqvist VH, Forbes H, Rast JE, Martin FZ, Zhong C, et al. Antiseizure medication use during pregnancy and children’s neurodevelopmental outcomes. Nat Commun. 2024;15(1):9640. pmid:39548057 * [ View Article ](https://doi.org/10.1038/s41467-024-53813-1 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/39548057 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Antiseizure+medication+use+during+pregnancy+and+children%E2%80%99s+neurodevelopmental+outcomes+Madley-Dowd+2024 "Go to article in Google Scholar") 3. 3. Sullivan C, Kerr A, Cahill M, Flynn AC, O’Shaughnessy F, Cleary B, et al. Estimating the prevalence of prescribed medication use in pregnancy with a systematic review and meta-analysis. Drug Saf. 2026;49(8):899–920. pmid:41922857 * [ View Article ](https://doi.org/10.1007/s40264-026-01664-8 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/41922857 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Estimating+the+prevalence+of+prescribed+medication+use+in+pregnancy+with+a+systematic+review+and+meta-analysis+Sullivan+2026 "Go to article in Google Scholar") 4. 4. Hasidim AA, Ben Shitrit I, Idan D, Michael T, Levy A, Pariente G, et al. First-trimester nonsteroidal anti-inflammatory drugs exposure and risk of major congenital malformations: A retrospective register-based cohort study. PLoS Med. 2026;23(5):e1005063. pmid:42133587 * [ View Article ](https://doi.org/10.1371/journal.pmed.1005063 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/42133587 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=First-trimester+nonsteroidal+anti-inflammatory+drugs+exposure+and+risk+of+major+congenital+malformations%3A+A+retrospective+register-based+cohort+study+Hasidim+2026 "Go to article in Google Scholar") 5. 5. Tran A, Zureik M, Sibiude J, Miranda S, Drouin J, Marty L, et al. First-trimester exposure to macrolides and risk of major congenital malformations compared with amoxicillin: A French nationwide cohort study. PLoS Med. 2025;22(4):e1004576. pmid:40233106 * [ View Article ](https://doi.org/10.1371/journal.pmed.1004576 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/40233106 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=First-trimester+exposure+to+macrolides+and+risk+of+major+congenital+malformations+compared+with+amoxicillin%3A+A+French+nationwide+cohort+study+Tran+2025 "Go to article in Google Scholar") 6. 6. Choi E-Y, Bea S, Lee H, Choi A, Han JY, Kang EH, et al. Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study in Korea. PLoS Med. 2025;22(8):e1004677. pmid:40839560 * [ View Article ](https://doi.org/10.1371/journal.pmed.1004677 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/40839560 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Exposure+to+antibiotics+during+pregnancy+or+early+infancy+and+the+risk+of+autoimmune+disease+in+children%3A+A+nationwide+cohort+study+in+Korea+Choi+2025 "Go to article in Google Scholar") 7. 7. Shakhshir LA, Karain A, Pell JP, Hastie CE, Nelson SM, Fleming M. Prenatal exposure to asthma medications and risk of neurodevelopmental disorders and educational difficulties: A systematic review and meta-analysis. PLoS Med. 2026;23(6):e1005100. pmid:42224295 * [ View Article ](https://doi.org/10.1371/journal.pmed.1005100 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/42224295 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Prenatal+exposure+to+asthma+medications+and+risk+of+neurodevelopmental+disorders+and+educational+difficulties%3A+A+systematic+review+and+meta-analysis+Shakhshir+2026 "Go to article in Google Scholar") 8. 8. Jardine J, Gurol-Urganci I, Harris T, Hawdon J, Pasupathy D, van der Meulen J, et al. Associations between ethnicity and admission to intensive care among women giving birth: A cohort study. BJOG. 2022;129:733–42. * [ View Article ](https://doi.org/10.1111/1471-0528.16891 "Go to article") * [ Google Scholar ](http://scholar.google.com/scholar?q=Associations+between+ethnicity+and+admission+to+intensive+care+among+women+giving+birth%3A+A+cohort+study+Jardine+2022 "Go to article in Google Scholar") 9. 9. Manfrin A, Lee K, Pound J, Pirmohamed M, Raine J. Analysis of 4616 clinical trial initial submissions received by the Medicines and Healthcare products Regulatory Agency between February 2019 and October 2023. Br J Clin Pharmac
## Related Clinical Research

- [Does postmenopausal HRT raise migraine frequency or duration?](https://medichelpline.com/clinical-feed/medical-news-today-0-can-hrt-increase-migraine-frequency-duration-at-postmenopause.md)
- [Creatine for Healthy Aging: Examining a Decade of Use](https://medichelpline.com/clinical-feed/medical-news-today-0-age-appropriate-i-ve-taken-creatine-for-10-years-does-it-help-healthy-aging.md)
- [Spreading depolarization alters distant cortical connectivity after focal injury](https://medichelpline.com/clinical-feed/plos-one-10-spreading-depolarization-drives-distant-connectivity-changes-in-the-focally.md)
- [Delabelling Pediatric Amoxicillin Allergy Using Direct Oral Challenge in Northwestern Ontario](https://medichelpline.com/clinical-feed/pubmed-42629506.md) (DOI: 10.1007/s00431-026-07169-x)
- [Estimating WHO AWaRe Antibiotic Use Levels Based on Infection and Resistance Burden](https://medichelpline.com/clinical-feed/the-lancet-public-health-3-estimating-optimal-levels-of-who-access-watch-reserve-aware-antibiotic-use-in.md) (DOI: 10.1016/S2468-2667(26)00103-9)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.